Anacor Co-Founder Dr. Stephen Benkovic Awarded National Medal of Science

PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals today congratulates its Co-Founder, Dr. Stephen Benkovic, who was named as a recipient of the 2010 National Medal of Science, the highest honor bestowed by the President of the United States for lifetime achievement in scientific research.

Dr. Benkovic is being honored “for his seminal research that has changed our understanding of how enzymes function, singly or in complexes, and has lead to novel pharmaceuticals and biocatalysts.” He is the Evan Pugh Professor and Eberly Chair in Chemistry at the Pennsylvania State University.

“Steve’s research in novel chemistry provided the basis for Anacor’s boron chemistry platform,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals. “On behalf of all the employees at Anacor, we offer our sincere congratulations.”

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis and GSK 2251052, or GSK ‘052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been optioned for development by GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. For more information visit www.anacor.com.

Forward-Looking Statements

This press release may contain forward-looking statements that relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These statements reflect the views of Anacor as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.



CONTACT:

Anacor Pharmaceuticals
Geoffrey M. Parker, 650-543-7500
Chief Financial Officer
Anne Bowdidge, 650-543-7575
Investor Relations

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.